USRE44186E1 - Cyclopropyl-fused pyrrolidine-based inhibitors of dipeptidyl peptidase IV and method - Google Patents

Cyclopropyl-fused pyrrolidine-based inhibitors of dipeptidyl peptidase IV and method Download PDF

Info

Publication number
USRE44186E1
USRE44186E1 US13/308,658 US201113308658A USRE44186E US RE44186 E1 USRE44186 E1 US RE44186E1 US 201113308658 A US201113308658 A US 201113308658A US RE44186 E USRE44186 E US RE44186E
Authority
US
United States
Prior art keywords
compound
inhibitor
agent
mmol
pharmaceutically acceptable
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active, expires
Application number
US13/308,658
Inventor
Jeffrey A. Robl
Richard B. Sulsky
David J. Augeri
David R. Magnin
Lawrence G. Hamann
David A. Betebenner
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
AstraZeneca AB
Original Assignee
Bristol Myers Squibb Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
Priority to US18855500P priority Critical
Priority to US09/788,173 priority patent/US6395767B2/en
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=22693638&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=USRE44186(E1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Bristol Myers Squibb Co filed Critical Bristol Myers Squibb Co
Priority to US13/308,658 priority patent/USRE44186E1/en
Application granted granted Critical
Publication of USRE44186E1 publication Critical patent/USRE44186E1/en
Assigned to ASTRAZENECA AB reassignment ASTRAZENECA AB ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: BRISTOL-MYERS SQUIBB COMPANY
Assigned to ASTRAZENECA AB reassignment ASTRAZENECA AB CORRECTIVE ASSIGNMENT TO CORRECT THE ADDRESS PREVIOUSLY RECORDED ON REEL 032541 FRAME 0698. ASSIGNOR(S) HEREBY CONFIRMS THE ADDRESS OF THE ASSIGNEE SHOULD BE SE-151 85, SODERTALJE, SWEDEN. Assignors: BRISTOL-MYERS SQUIBB COMPANY
Active legal-status Critical Current
Adjusted expiration legal-status Critical

Links